Jan 09, 2024 / 03:30PM GMT
Eric Joseph J.P. Morgan-Analyst
Good morning. I'm Eric Joseph, senior biotech analyst with JPMorgan. Our first presenting company this morning is playing therapeutics. And presenting on behalf of the Company is C. CEO, O. Bernard Cooley, there will be a Q&A session after the presentation and just raise your hand, we'll get a mic over to you and for those tuning in via webcast, you can also submit questions through the ask-a-question icon. So and with that, no, Bernard.
Thanks.
Bernard Coulie Pliant Therapeutics - Inc. - CEO
Thanks, Eric. And first, I wanted to thank Eric and the JPMorgan team for giving us the opportunity to present today. As you know, with Pliant, our mission is to develop novel treatments for rare high medical need fibrotic diseases. And with that mission in mind, we have developed what we consider as the industry leading fibrosis platform, which is based on small molecule inhibition of integrins mediated TGF-beta activation. We know that TGF-beta is the main regulator of fibrosis, and we have shown that with our approach,
Pliant Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 09, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers